Moreover, the 36-month beta value for MYGN is 1.94. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 9 as “hold,” and 3 as “sell.”
The public float for MYGN is 86.02M and currently, short sellers hold a 6.39% of that float. On May 08, 2024, MYGN’s average trading volume was 662.03K shares.
MYGN) stock’s latest price update
Myriad Genetics, Inc. (NASDAQ: MYGN)’s stock price has soared by 18.25 in relation to previous closing price of 19.78. Nevertheless, the company has seen a gain of 20.13% in its stock price over the last five trading days. Seeking Alpha reported 2024-05-07 that Myriad Genetics, Inc. (NASDAQ:MYGN ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Matthew Scalo – Senior Vice President of Investor Relations Paul Diaz – President and Chief Executive Officer Mark Verratti – Chief Commercial Officer Sam Raha – Chief Operating Officer Scott Leffler – Chief Financial Officer Conference Call Participants Matthew Sykes – Goldman Sachs Doug Schenkel – Wolfe Research, LLC Daniel Brennan – TD Cowen Puneet Souda – Leerink Partners LLC Andrew Cooper – Raymond James Financial, Inc. Rachel Vatnsdal – JPMorgan Chase & Co. Subbu Nambi – Guggenheim Securities, LLC Jacob Krahenbuhl – Stephens Inc. John Kim – Bank of America Operator Thank you for standing by, and welcome to Myriad Genetics First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
MYGN’s Market Performance
MYGN’s stock has risen by 20.13% in the past week, with a monthly rise of 12.02% and a quarterly rise of 6.41%. The volatility ratio for the week is 4.59% while the volatility levels for the last 30 days are 3.96% for Myriad Genetics, Inc.. The simple moving average for the past 20 days is 22.07% for MYGN’s stock, with a 22.80% simple moving average for the past 200 days.
Analysts’ Opinion of MYGN
Piper Sandler, on the other hand, stated in their research note that they expect to see MYGN reach a price target of $23. The rating they have provided for MYGN stocks is “Neutral” according to the report published on December 21st, 2023.
Wells Fargo gave a rating of “Equal Weight” to MYGN, setting the target price at $20 in the report published on December 19th of the previous year.
MYGN Trading at 13.35% from the 50-Day Moving Average
After a stumble in the market that brought MYGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.39% of loss for the given period.
Volatility was left at 3.96%, however, over the last 30 days, the volatility rate increased by 4.59%, as shares surge +16.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.17% upper at present.
During the last 5 trading sessions, MYGN rose by +20.90%, which changed the moving average for the period of 200-days by +6.90% in comparison to the 20-day moving average, which settled at $19.32. In addition, Myriad Genetics, Inc. saw 22.20% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MYGN starting from Riggsbee Richard Bryan, who sale 30,000 shares at the price of $19.09 back on Dec 01 ’23. After this action, Riggsbee Richard Bryan now owns 291,812 shares of Myriad Genetics, Inc., valued at $572,835 using the latest closing price.
Riggsbee Richard Bryan, the Chief Financial Officer of Myriad Genetics, Inc., sale 30,000 shares at $15.69 during a trade that took place back on Nov 01 ’23, which means that Riggsbee Richard Bryan is holding 321,812 shares at $470,622 based on the most recent closing price.
Stock Fundamentals for MYGN
Current profitability levels for the company are sitting at:
- -0.37 for the present operating margin
- 0.69 for the gross margin
The net margin for Myriad Genetics, Inc. stands at -0.37. The total capital return value is set at -0.29. Equity return is now at value -29.41, with -20.58 for asset returns.
Based on Myriad Genetics, Inc. (MYGN), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -0.32. The debt to equity ratio resting at 0.29. The interest coverage ratio of the stock is -93.79.
Currently, EBITDA for the company is -67.8 million with net debt to EBITDA at -0.59. When we switch over and look at the enterprise to sales, we see a ratio of 2.99. The receivables turnover for the company is 6.38for trailing twelve months and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.99.
Conclusion
To wrap up, the performance of Myriad Genetics, Inc. (MYGN) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
